B. Hall

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

S. Hoffman, D. Kaslow, R. Anders, 1998, The Journal of infectious diseases.

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

V. A. Stewart, J. Wittes, M. Thera, 2005, Vaccine.

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

V. A. Stewart, Marie-Claude Dubois, In-Kyu Yoon, 2010, Vaccine.

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.

M. Demoitié, W. Ballou, Joe D. Cohen, 2008, Vaccine.

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

V. A. Stewart, J. Wittes, M. Thera, 2005, Vaccine.